Biogen Inc. ( NASDAQ: BIIB) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ET Great. Good morning, everybody. Happy to be moderating my annual panel where Priya has to listen to me ...

The move is just part of the drugmaker’s original plan, however, which was to also submit a marketing application for a once-weekly, subcutaneous formulation of Leqembi (lecanemab), according to ...

A monoclonal antibody called Leqembi (lecanemab) has been approved by the Food and Drug ... Dietary supplements and cognitive function, dementia, and Alzheimer’s disease. Cunnane SC, Chouinard-Watkins ...

Following CHMP's reaffirmation, after having considered the additional information requested by the European Commission (EC), the EC will resume the decision-making process for lecanemab's ...

Eisai remains committed to ensuring eligible Australians with early Alzheimer's disease can access lecanemab and is exploring options to achieve this, including potentially seeking review by the ...

Researchers from the Drug Safety Research Unit are calling for the robust monitoring of the safety of lecanemab, a promising new drug to treat Alzheimer’s Disease (AD). In a review article, published ...

In October 2024, the TGA made the decision not to register lecanemab in Australia for the treatment of patients with early AD. In December 2024, Eisai requested reconsideration of the decision ...

We respond to the disappointing decision NICE has made to not recommend donanemab and lecanemab on the NHS. On Thursday, 6 March, NICE published further draft guidance for public consultation that ...

Today we’ve published further draft guidance for public consultation that continues to not recommend Alzheimer’s treatments donanemab and lecanemab. Our independent committee said last year that the ...

There are many companies to work for in South Carolina, but some are better than others. Be it higher pay, more benefits, or quality working conditions, some companies just have more to offer.